Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T17:21:35.152Z.
Calculation as of: 2026-10-06T17:21:35.152Z.
Quote observation: 2026-10-06T17:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
EARNINGS YIELD
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.90B
Earnings Yield
N/A
TTM Avg
31.62%
3Y Avg
31.62%
5Y Avg
31.62%
Market Cap
$1.95B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.89B
Earnings Yield
2.65%
TTM Avg
2.81%
3Y Avg
2.81%
5Y Avg
0.91%
Market Cap
$1.98B
Earnings Yield
6.76%
TTM Avg
6.22%
3Y Avg
3.42%
5Y Avg
3.42%
Market Cap
$1.85B
Earnings Yield
2.20%
TTM Avg
1.44%
3Y Avg
2.50%
5Y Avg
2.86%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A | 31.62% | 31.62% | 31.62% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.95B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.89B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 2.65% | 2.81% | 2.81% | 0.91% |
| AxoGen, Inc. (AXGN)vs › | $1.97B | N/A | 98.76% | 98.76% | 79.11% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 6.76% | 6.22% | 3.42% | 3.42% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 2.20% | 1.44% | 2.50% | 2.86% |
| Azenta, Inc. (AZTA)vs › | $1.84B | N/A | 1.68% | 5.59% | 5.05% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.83B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
